4Drucker DJ,Nauck MA. The incretin system:glucagonlike peptide-1 re- ceptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet,2006,368 : 1696-1705.
5Salehi M, Aulinger BA, D'Alessio DA. Targeting 13-cell mass in type 2 diabetes:promise and limetations of new drugs based on incretins. En- doer Rev ,2008,29:367-379.
6Mannucci E,Tesi F,Bardini G,et al. Effects of mefformin on glucagon- like peptide-1 levels in obese patients with and without Type 2 diabe- tes. Diabetes Nutr Metab,2004,17:336-342.
7Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon- like peptide 1 by biguanide compounds. Bioehem Biophys Res Com- mun ,2002,298:779-784.
8Knop FK. Reduced incretin effect in type 2 diabetes:cause or conse- quence of the diabetic state? Diabetes,2007,56:1951-1959.
9Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl pepti- dase-IV inhibitor vildagliptin on incretin hormones. Islet function, and postprandial glyeemia in subjects with impaired glucose tolerance. Dia- betes care ,2008,31:30-35.
10Krishnamurti U, Steffes MW. Glycohemoglobin : a primary predictor of the development or reversal of complications of diabetes mellitus [ J]. Clin Chem,2001,47 (7) : 1157-1165.
